PITTSBURGH, July 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq:
MYL) today announced that it has launched Telmisartan Tablets USP,
20 mg, 40 mg and 80 mg, the generic version of Boehringer
Ingelheim's Micardis® Tablets. Mylan received final approval from
the U.S. Food and Drug Administration (FDA) for its Abbreviated New
Drug Application (ANDA) for this product, which is indicated for
the treatment of hypertension, to lower blood pressure.
Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, had U.S. sales
of approximately $259.2 million for
the 12 months ending March 31, 2014,
according to IMS Health.
Currently, Mylan has 305 ANDAs pending FDA approval representing
$107.2 billion in annual brand sales,
according to IMS Health. Forty-two of these pending ANDAs are
potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12
months ending Dec. 31, 2013,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.